Brain-heart Interaction in Coronary Plaque Stability and Cardiovascular Events

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

300 participants

Study Classification

OBSERVATIONAL

Study Start Date

2015-01-01

Study Completion Date

2022-12-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The effect of brain-heart interaction remains unclear. The study aims to investigate the biological interconnection between brain neural activity and coronary plaque morphological and inflammatory features, as well as their connection with clinical outcomes.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Correlation Between Coronary Artery and Brain Study

NCT05813405

Cardiovascular and Cerebrovascular Diseases

NOT_YET_RECRUITING

Ruijin Neurobank of Alzheimer's Disease and Dementia

NCT05623124

Dementia

RECRUITING

Feedback Loop Between Intracranial Atherosclerosis and Cerebral Small Vessel Disease

NCT05677607

ICAS - Intracranial Atherosclerosis Cerebral Small Vessel Diseases

RECRUITING

Multi-Modality Imaging Standard Cohort Of Cerebrovascular Disease

NCT06925178

Cerebrovascular Disease

RECRUITING

Evaluation of Brain Health and Surgical Efficacy in Patients With Carotid Artery Stenosis

NCT05848921

Carotid Artery Stenosis Image

NOT_YET_RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Brain neural activity assessed by resting amygdalar activity (AmygA) can predict cardiovascular events. However, its biological interconnection with plaque vulnerability i is not fully understood. Coronary computed tomographic angiography (CCTA) is a non-invasive technique that enables comprehensive assessment of morphological characteristics of coronary atheroma and estimates the level of plaque instability. Recently, perivascular fat attenuation index (FAI) enables assessment of coronary inflammation by analyzing changes of perivascular adipose tissue attenuation in CCTA.

18F-fluorodeoxyglucose-positron emission tomography/computed tomography (18F-FDG-PET/CT) enables simultaneous estimation of multi-system activities including brain neural activity and hematopoiesis.

The present study aims to use ¹⁸F-FDG PET/CT to assess the AmygA, and to investigate its association with CCTA assessed plaque morphological and inflammatory features as well as their ability in predicting future cardiovascular disease events.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Coronary Artery Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

CCTA imaging with 18F-FDG-PET/CT assessment

Group of patients with 18F-FDG-PET/CT imaging and Coronary Computed Tomographic Angiography within 90 days

CCTA and 18F-FDG-PET/CT

Intervention Type DIAGNOSTIC_TEST

18F-FDG-PET/CT imaging and comprehensive assessment of coronary plaque with CCTA within 90 days

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

CCTA and 18F-FDG-PET/CT

18F-FDG-PET/CT imaging and comprehensive assessment of coronary plaque with CCTA within 90 days

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 1\) Age: greater than 20
* 2\) Patients either absence of prior cancer or remission from cancer for at least 1 year prior to imaging and throughout the follow-up period;
* 3\) Patients absence of acute or chronic inﬂammatory or autoimmune disease at the time of imaging;
* 4\) Patients with CCTA performed within 90 days of 18F-FDG PET/CT scan as part of routine clinical practice
* 5\) Patients with diameter stenosis \>30% by CCTA but without coronary revascularization

Exclusion Criteria

* 1\) Complex coronary lesion (ostial lesion, unprotected left main lesion, chronic total occlusion, grafted vessels, etc)
* 2\) Coronary lesion with heavy calcification
* 3\) Chronic renal insufficiency (Serum creatinine \>2.0mg/dL)
* 4\) Severe liver dysfunction (aspartate transaminase or alanine transferase \> 5 times of upper normal limit)
* 5\) Pregnancy or potential pregnancy
* 6\) Life expectancy less than 5 year

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No